aumolertinib
Small moleculeexperimental
Clinical trial activity
17 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
11
Phase 3
5
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02981108)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptorINHIBITOR
Epidermal growth factor receptor inhibitor
Epidermal growth factor receptor erbB1 inhibitor
Targets EGFR with activating or T790M mutations.
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C- Mol. weight
- 525.66 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4761468 ↗
Also known as
- hs-10296
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07183189 | Phase 3 | Oct 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06926413 | Phase 1 | Feb 20, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06752408 | Phase 2 | Dec 17, 2024 | Chinese Academy of Medical Sciences, Peking University |
| NCT07130916 | Phase 1 | Dec 5, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06227897 | Phase 2 | Jun 1, 2024 | Sun Yat-Sen University |
| NCT06417008 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2024 | Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd., Tianjin Medical University |
| NCT06102928 | N/A | Oct 30, 2023 | Kunming Medical University |
| NCT05946460 | Phase 2 | Jul 10, 2023 | Guangzhou Medical University |
| NCT05778149 | Phase 2 | Mar 31, 2023 | Tianjin Medical University |
| NCT05493501 | Phase 3 | Jul 29, 2022 | EQRx, Inc. |
| NCT05199610 | Phase 1 | Mar 22, 2022 | EQRx, Inc. |
| NCT04922138 | Phase 2 | Oct 15, 2021 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiao Tong University, Shanghai Chest Hospital, Shanghai, China |
| NCT04923906 | Phase 3 | Aug 1, 2021 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiao Tong University |
| NCT04969965 | Phase 1 | Jun 21, 2021 | EQRx, Inc. |
| NCT03904823 | Phase 2 | Apr 30, 2019 | Hengrui Therapeutics, Inc., Huazhong University of Science and Technology |
| NCT03849768 | Phase 3 | Feb 1, 2019 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Pacific Cancer Medical Center Inc. |
| NCT02981108 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 7 | 6 | 3 | 2016 |
| EQRx, Inc. | For profit | 3 | 3 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 1 | 2 | 2024 |
| Jiao Tong University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Tianjin Medical University | Academic/Hospital | 2 | 1 | 2 | 2023 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Kunming Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Pacific Cancer Medical Center Inc. | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Shanghai Chest Hospital, Shanghai, China | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
14 organizations
Page 1 / 1